{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:41:00Z","timestamp":1784893260995,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Wendy Walk Foundation"},{"name":"Singapore Ministry of Health\u2019s National Medical Research Council","award":["NMRC\/STaR\/0021\/2014"],"award-info":[{"award-number":["NMRC\/STaR\/0021\/2014"]}]},{"DOI":"10.13039\/501100001459","name":"Singapore Ministry of Education","doi-asserted-by":"crossref","award":["MOE2013-T2-2-150"],"award-info":[{"award-number":["MOE2013-T2-2-150"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Singapore Ministry of Health\u2019s National Medical Research Council","award":["NMRC\/CG\/012\/2013"],"award-info":[{"award-number":["NMRC\/CG\/012\/2013"]}]},{"name":"Singapore Ministry of Health\u2019s National Medical Research Council","award":["CGAug16M005"],"award-info":[{"award-number":["CGAug16M005"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA200992-04"],"award-info":[{"award-number":["R01 CA200992-04"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001475","name":"Nanyang Technological University","doi-asserted-by":"publisher","award":["NTU presidential postdoctoral fellowship"],"award-info":[{"award-number":["NTU presidential postdoctoral fellowship"]}],"id":[{"id":"10.13039\/501100001475","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Proteasome inhibitors, such as bortezomib and carfilzomib, have shown efficacy in anti-cancer therapy in hematological diseases but not in solid cancers. Here, we found that liposarcomas (LPS) are susceptible to proteasome inhibition, and identified drugs that synergize with carfilzomib, such as selinexor, an inhibitor of XPO1-mediated nuclear export. Through quantitative nuclear protein profiling and phospho-kinase arrays, we identified potential mode of actions of this combination, including interference with ribosome biogenesis and inhibition of pro-survival kinase PRAS40. Furthermore, by assessing global protein levels changes, FADS2, a key enzyme regulating fatty acids synthesis, was found down-regulated after proteasome inhibition. Interestingly, SC26196, an inhibitor of FADS2, synergized with carfilzomib. Finally, to identify further combinational options, we performed high-throughput drug screening and uncovered novel drug interactions with carfilzomib. For instance, cyclosporin A, a known immunosuppressive agent, enhanced carfilzomib\u2019s efficacy in vitro and in vivo. Altogether, these results demonstrate that carfilzomib and its combinations could be repurposed for LPS clinical management.<\/jats:p>","DOI":"10.1007\/s00018-020-03620-w","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T20:02:46Z","timestamp":1598472166000},"page":"1837-1851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2294-7815","authenticated-orcid":false,"given":"Maya","family":"Jeitany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishvaryaa","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushkar","family":"Dakle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Kanojia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineeth","family":"Mukundan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Yi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef","family":"Landesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Leong","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3582-2253","authenticated-orcid":false,"given":"Dennis","family":"Kappei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Phillip","family":"Koeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"issue":"2","key":"3620_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0955-0674(95)80031-X","volume":"7","author":"M Hochstrasser","year":"1995","unstructured":"Hochstrasser M (1995) Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 7(2):215\u2013223","journal-title":"Curr Opin Cell Biol"},{"issue":"13","key":"3620_CR2","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1158\/0008-5472.can-06-4086","volume":"67","author":"SD Demo","year":"2007","unstructured":"Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67(13):6383\u20136391. https:\/\/doi.org\/10.1158\/0008-5472.can-06-4086","journal-title":"Cancer Res"},{"issue":"7","key":"3620_CR3","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3109\/10428194.2010.483303","volume":"51","author":"G Cavaletti","year":"2010","unstructured":"Cavaletti G, Jakubowiak AJ (2010) Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 51(7):1178\u20131187. https:\/\/doi.org\/10.3109\/10428194.2010.483303","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"3620_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.cell.2011.12.030","volume":"148","author":"EM Huber","year":"2012","unstructured":"Huber EM, Basler M, Schwab R, Heinemeyer W, Kirk CJ, Groettrup M, Groll M (2012) Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 148(4):727\u2013738. https:\/\/doi.org\/10.1016\/j.cell.2011.12.030","journal-title":"Cell"},{"issue":"8","key":"3620_CR5","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1021\/acscentsci.7b00252","volume":"3","author":"PM Cromm","year":"2017","unstructured":"Cromm PM, Crews CM (2017) The proteasome in modern drug discovery: second life of a highly valuable drug target. ACS Cent Sci 3(8):830\u2013838. https:\/\/doi.org\/10.1021\/acscentsci.7b00252","journal-title":"ACS Cent Sci"},{"issue":"6","key":"3620_CR6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","volume":"8","author":"RC Kane","year":"2003","unstructured":"Kane RC, Bross PF, Farrell AT, Pazdur R (2003) Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8(6):508\u2013513","journal-title":"Oncologist"},{"issue":"9","key":"3620_CR7","first-page":"591","volume":"10","author":"R Vij","year":"2012","unstructured":"Vij R (2012) Carfilzomib in multiple myeloma. Clin Adv Hematol Oncol 10(9):591\u2013593","journal-title":"Clin Adv Hematol Oncol"},{"issue":"10","key":"3620_CR8","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.2217\/fon.14.30","volume":"10","author":"Z Huang","year":"2014","unstructured":"Huang Z, Wu Y, Zhou X, Xu J, Zhu W, Shu Y, Liu P (2014) Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials. Future Oncol 10(10):1795\u20131807. https:\/\/doi.org\/10.2217\/fon.14.30","journal-title":"Future Oncol"},{"issue":"8","key":"3620_CR9","doi-asserted-by":"publisher","first-page":"e20294","DOI":"10.1371\/journal.pone.0020294","volume":"6","author":"F Ducimetiere","year":"2011","unstructured":"Ducimetiere F, Lurkin A, Ranchere-Vince D, Decouvelaere AV, Peoc\u2019h M, Istier L, Chalabreysse P, Muller C, Alberti L, Bringuier PP, Scoazec JY, Schott AM, Bergeron C, Cellier D, Blay JY, Ray-Coquard I (2011) Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS ONE 6(8):e20294. https:\/\/doi.org\/10.1371\/journal.pone.0020294","journal-title":"PLoS ONE"},{"issue":"4","key":"3620_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1053\/adpa.2000.8133","volume":"4","author":"AP Dei Tos","year":"2000","unstructured":"Dei Tos AP (2000) Liposarcoma: new entities and evolving concepts. Ann Diagn Pathol 4(4):252\u2013266. https:\/\/doi.org\/10.1053\/adpa.2000.8133","journal-title":"Ann Diagn Pathol"},{"issue":"4","key":"3620_CR11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/08998280.2008.11928435","volume":"21","author":"S Steen","year":"2008","unstructured":"Steen S, Stephenson G (2008) Current treatment of soft tissue sarcoma. Proc (Bayl Univ Med Cent) 21(4):392\u2013396","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"15","key":"3620_CR12","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1158\/1078-0432.ccr-16-2632","volume":"23","author":"JS Nair","year":"2017","unstructured":"Nair JS, Musi E, Schwartz GK (2017) Selinexor (KPT-330) induces tumor suppression through nuclear sequestration of IkappaB and downregulation of surviving. Clin Cancer Res 23(15):4301\u20134311. https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-2632","journal-title":"Clin Cancer Res"},{"issue":"7757","key":"3620_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, Aguet F, Weir BA, Rothberg MV, Paolella BR, Lawrence MS, Akbani R, Lu Y, Tiv HL, Gokhale PC, de Weck A, Mansour AA, Oh C, Shih J, Hadi K, Rosen Y, Bistline J, Venkatesan K, Reddy A, Sonkin D, Liu M, Lehar J, Korn JM, Porter DA, Jones MD, Golji J, Caponigro G, Taylor JE, Dunning CM, Creech AL, Warren AC, McFarland JM, Zamanighomi M, Kauffmann A, Stransky N, Imielinski M, Maruvka YE, Cherniack AD, Tsherniak A, Vazquez F, Jaffe JD, Lane AA, Weinstock DM, Johannessen CM, Morrissey MP, Stegmeier F, Schlegel R, Hahn WC, Getz G, Mills GB, Boehm JS, Golub TR, Garraway LA, Sellers WR (2019) Next-generation characterization of the cancer cell line encyclopedia. Nature 569(7757):503\u2013508. https:\/\/doi.org\/10.1038\/s41586-019-1186-3","journal-title":"Nature"},{"issue":"6","key":"3620_CR14","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"Consortium GT","year":"2013","unstructured":"Consortium GT (2013) The genotype-tissue expression (GTEx) project. Nat Genet 45(6):580\u2013585. https:\/\/doi.org\/10.1038\/ng.2653","journal-title":"Nat Genet"},{"issue":"10","key":"3620_CR15","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Cancer Genome Atlas Research, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM (2013) The cancer genome atlas pan-cancer analysis project. Nat Genet 45(10):1113\u20131120. https:\/\/doi.org\/10.1038\/ng.2764","journal-title":"Nat Genet"},{"issue":"4","key":"3620_CR16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nbt.3772","volume":"35","author":"J Vivian","year":"2017","unstructured":"Vivian J, Rao AA, Nothaft FA, Ketchum C, Armstrong J, Novak A, Pfeil J, Narkizian J, Deran AD, Musselman-Brown A, Schmidt H, Amstutz P, Craft B, Goldman M, Rosenbloom K, Cline M, O\u2019Connor B, Hanna M, Birger C, Kent WJ, Patterson DA, Joseph AD, Zhu J, Zaranek S, Getz G, Haussler D, Paten B (2017) Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol 35(4):314\u2013316. https:\/\/doi.org\/10.1038\/nbt.3772","journal-title":"Nat Biotechnol"},{"issue":"5","key":"3620_CR17","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","volume":"154","author":"A Basu","year":"2013","unstructured":"Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, Ebright RY, Stewart ML, Ito D, Wang S, Bracha AL, Liefeld T, Wawer M, Gilbert JC, Wilson AJ, Stransky N, Kryukov GV, Dancik V, Barretina J, Garraway LA, Hon CS, Munoz B, Bittker JA, Stockwell BR, Khabele D, Stern AM, Clemons PA, Shamji AF, Schreiber SL (2013) An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154(5):1151\u20131161. https:\/\/doi.org\/10.1016\/j.cell.2013.08.003","journal-title":"Cell"},{"issue":"1","key":"3620_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-017-0540-x","volume":"10","author":"D Kanojia","year":"2017","unstructured":"Kanojia D, Garg M, Martinez J, Ta M, Luty SB, Doan NB, Said JW, Forscher C, Tyner JW, Koeffler HP (2017) Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. J Hematol Oncol 10(1):173. https:\/\/doi.org\/10.1186\/s13045-017-0540-x","journal-title":"J Hematol Oncol"},{"issue":"48","key":"3620_CR19","doi-asserted-by":"publisher","first-page":"78883","DOI":"10.18632\/oncotarget.12428","volume":"7","author":"T Kashyap","year":"2016","unstructured":"Kashyap T, Argueta C, Aboukameel A, Unger TJ, Klebanov B, Mohammad RM, Muqbil I, Azmi AS, Drolen C, Senapedis W, Lee M, Kauffman M, Shacham S, Landesman Y (2016) Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-kappaB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget 7(48):78883\u201378895. https:\/\/doi.org\/10.18632\/oncotarget.12428","journal-title":"Oncotarget"},{"issue":"1","key":"3620_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/1535-7163.mct-15-0488","volume":"15","author":"S Rosebeck","year":"2016","unstructured":"Rosebeck S, Alonge MM, Kandarpa M, Mayampurath A, Volchenboum SL, Jasielec J, Dytfeld D, Maxwell SP, Kraftson SJ, McCauley D, Shacham S, Kauffman M, Jakubowiak AJ (2016) Synergistic myeloma cell death via novel intracellular activation of caspase-10-dependent apoptosis by carfilzomib and selinexor. Mol Cancer Ther 15(1):60\u201371. https:\/\/doi.org\/10.1158\/1535-7163.mct-15-0488","journal-title":"Mol Cancer Ther"},{"issue":"48","key":"3620_CR21","doi-asserted-by":"publisher","first-page":"78896","DOI":"10.18632\/oncotarget.12969","volume":"7","author":"JG Turner","year":"2016","unstructured":"Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM (2016) XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IkappaBalpha and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget 7(48):78896\u201378909. https:\/\/doi.org\/10.18632\/oncotarget.12969","journal-title":"Oncotarget"},{"issue":"5","key":"3620_CR22","doi-asserted-by":"publisher","first-page":"7521","DOI":"10.18632\/oncotarget.13485","volume":"8","author":"M Garg","year":"2017","unstructured":"Garg M, Kanojia D, Mayakonda A, Said JW, Doan NB, Chien W, Ganesan TS, Chuang LS, Venkatachalam N, Baloglu E, Shacham S, Kauffman M, Koeffler HP (2017) Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma. Oncotarget 8(5):7521\u20137532. https:\/\/doi.org\/10.18632\/oncotarget.13485","journal-title":"Oncotarget"},{"issue":"3","key":"3620_CR23","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1074\/mcp.m112.024877","volume":"12","author":"K Thakar","year":"2013","unstructured":"Thakar K, Karaca S, Port SA, Urlaub H, Kehlenbach RH (2013) Identification of CRM1-dependent nuclear export cargos using quantitative mass spectrometry. Mol Cell Proteomics 12(3):664\u2013678. https:\/\/doi.org\/10.1074\/mcp.m112.024877","journal-title":"Mol Cell Proteomics"},{"issue":"20","key":"3620_CR24","doi-asserted-by":"publisher","first-page":"5614","DOI":"10.1158\/0008-5472.can-17-1323","volume":"77","author":"F Conforti","year":"2017","unstructured":"Conforti F, Zhang X, Rao G, De Pas T, Yonemori Y, Rodriguez JA, McCutcheon JN, Rahhal R, Alberobello AT, Wang Y, Zhang YW, Guha U, Giaccone G (2017) Therapeutic effects of XPO1 inhibition in thymic epithelial tumors. Cancer Res 77(20):5614\u20135627. https:\/\/doi.org\/10.1158\/0008-5472.can-17-1323","journal-title":"Cancer Res"},{"issue":"10","key":"3620_CR25","doi-asserted-by":"publisher","first-page":"e1000522","DOI":"10.1371\/journal.pbio.1000522","volume":"8","author":"T Wild","year":"2010","unstructured":"Wild T, Horvath P, Wyler E, Widmann B, Badertscher L, Zemp I, Kozak K, Csucs G, Lund E, Kutay U (2010) A protein inventory of human ribosome biogenesis reveals an essential function of exportin 5 in 60S subunit export. PLoS Biol 8(10):e1000522. https:\/\/doi.org\/10.1371\/journal.pbio.1000522","journal-title":"PLoS Biol"},{"issue":"7605","key":"3620_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nature17942","volume":"534","author":"S Wu","year":"2016","unstructured":"Wu S, Tutuncuoglu B, Yan K, Brown H, Zhang Y, Tan D, Gamalinda M, Yuan Y, Li Z, Jakovljevic J, Ma C, Lei J, Dong MQ, Woolford JL Jr, Gao N (2016) Diverse roles of assembly factors revealed by structures of late nuclear pre-60S ribosomes. Nature 534(7605):133\u2013137. https:\/\/doi.org\/10.1038\/nature17942","journal-title":"Nature"},{"key":"3620_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ctdb.2016.08.004","volume":"123","author":"AR Rodan","year":"2017","unstructured":"Rodan AR, Jenny A (2017) WNK kinases in development and disease. Curr Top Dev Biol 123:1\u201347. https:\/\/doi.org\/10.1016\/bs.ctdb.2016.08.004","journal-title":"Curr Top Dev Biol"},{"issue":"40","key":"3620_CR28","doi-asserted-by":"publisher","first-page":"69076","DOI":"10.18632\/oncotarget.17299","volume":"8","author":"D Lv","year":"2017","unstructured":"Lv D, Guo L, Zhang T, Huang L (2017) PRAS40 signaling in tumor. Oncotarget 8(40):69076\u201369085. https:\/\/doi.org\/10.18632\/oncotarget.17299","journal-title":"Oncotarget"},{"issue":"1","key":"3620_CR29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/nrm.2017.73","volume":"19","author":"R Gomez-Pastor","year":"2018","unstructured":"Gomez-Pastor R, Burchfiel ET, Thiele DJ (2018) Regulation of heat shock transcription factors and their roles in physiology and disease. Nat Rev Mol Cell Biol 19(1):4\u201319. https:\/\/doi.org\/10.1038\/nrm.2017.73","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"3620_CR30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2012.06.031","volume":"150","author":"ML Mendillo","year":"2012","unstructured":"Mendillo ML, Santagata S, Koeva M, Bell GW, Hu R, Tamimi RM, Fraenkel E, Ince TA, Whitesell L, Lindquist S (2012) HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell 150(3):549\u2013562. https:\/\/doi.org\/10.1016\/j.cell.2012.06.031","journal-title":"Cell"},{"key":"3620_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-3-319-07320-0_7","volume":"824","author":"F Tosi","year":"2014","unstructured":"Tosi F, Sartori F, Guarini P, Olivieri O, Martinelli N (2014) Delta-5 and delta-6 desaturases: crucial enzymes in polyunsaturated fatty acid-related pathways with pleiotropic influences in health and disease. Adv Exp Med Biol 824:61\u201381. https:\/\/doi.org\/10.1007\/978-3-319-07320-0_7","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"3620_CR32","first-page":"157","volume":"287","author":"MG Obukowicz","year":"1998","unstructured":"Obukowicz MG, Welsch DJ, Salsgiver WJ, Martin-Berger CL, Chinn KS, Duffin KL, Raz A, Needleman P (1998) Novel, selective delta6 or delta5 fatty acid desaturase inhibitors as antiinflammatory agents in mice. J Pharmacol Exp Ther 287(1):157\u2013166","journal-title":"J Pharmacol Exp Ther"},{"key":"3620_CR33","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-nb2019-085","author":"E Dolgin","year":"2019","unstructured":"Dolgin E (2019) XPO1 inhibitor approved for multiple myeloma. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.cd-nb2019-085","journal-title":"Cancer Discov"},{"issue":"26","key":"3620_CR34","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1200\/jco.2016.67.6346","volume":"34","author":"MM Gounder","year":"2016","unstructured":"Gounder MM, Zer A, Tap WD, Salah S, Dickson MA, Gupta AA, Keohan ML, Loong HH, D\u2019Angelo SP, Baker S, Condy M, Nyquist-Schultz K, Tanner L, Erinjeri JP, Jasmine FH, Friedlander S, Carlson R, Unger TJ, Saint-Martin JR, Rashal T, Ellis J, Kauffman M, Shacham S, Schwartz GK, Abdul Razak AR (2016) Phase IB Study of Selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J Clin Oncol 34(26):3166\u20133174. https:\/\/doi.org\/10.1200\/jco.2016.67.6346","journal-title":"J Clin Oncol"},{"issue":"16","key":"3620_CR35","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1038\/sj.emboj.7600752","volume":"24","author":"J Rouquette","year":"2005","unstructured":"Rouquette J, Choesmel V, Gleizes PE (2005) Nuclear export and cytoplasmic processing of precursors to the 40S ribosomal subunits in mammalian cells. EMBO J 24(16):2862\u20132872. https:\/\/doi.org\/10.1038\/sj.emboj.7600752","journal-title":"EMBO J"},{"issue":"Pt 12","key":"3620_CR36","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1242\/jcs.00464","volume":"116","author":"F Thomas","year":"2003","unstructured":"Thomas F, Kutay U (2003) Biogenesis and nuclear export of ribosomal subunits in higher eukaryotes depend on the CRM1 export pathway. J Cell Sci 116(Pt 12):2409\u20132419. https:\/\/doi.org\/10.1242\/jcs.00464","journal-title":"J Cell Sci"},{"issue":"6","key":"3620_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41419-019-1627-9","volume":"10","author":"ZC Zhu","year":"2019","unstructured":"Zhu ZC, Liu JW, Yang C, Zhao M, Xiong ZQ (2019) XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis. Cell Death Dis 10(6):395. https:\/\/doi.org\/10.1038\/s41419-019-1627-9","journal-title":"Cell Death Dis"},{"issue":"2","key":"3620_CR38","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00280-017-3489-0","volume":"81","author":"MSF Roeten","year":"2018","unstructured":"Roeten MSF, Cloos J, Jansen G (2018) Positioning of proteasome inhibitors in therapy of solid malignancies. Cancer Chemother Pharmacol 81(2):227\u2013243. https:\/\/doi.org\/10.1007\/s00280-017-3489-0","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"3620_CR39","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrc2222","volume":"7","author":"JA Menendez","year":"2007","unstructured":"Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7(10):763\u2013777. https:\/\/doi.org\/10.1038\/nrc2222","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3620_CR40","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3892\/ijo_00000616","volume":"36","author":"AM Olsen","year":"2010","unstructured":"Olsen AM, Eisenberg BL, Kuemmerle NB, Flanagan AJ, Morganelli PM, Lombardo PS, Swinnen JV, Kinlaw WB (2010) Fatty acid synthesis is a therapeutic target in human liposarcoma. Int J Oncol 36(5):1309\u20131314. https:\/\/doi.org\/10.3892\/ijo_00000616","journal-title":"Int J Oncol"},{"issue":"15","key":"3620_CR41","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1111\/j.1742-4658.2012.08644.x","volume":"279","author":"CR Santos","year":"2012","unstructured":"Santos CR, Schulze A (2012) Lipid metabolism in cancer. FEBS J 279(15):2610\u20132623. https:\/\/doi.org\/10.1111\/j.1742-4658.2012.08644.x","journal-title":"FEBS J"},{"issue":"12","key":"3620_CR42","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1158\/1535-7163.mct-08-0558","volume":"7","author":"JL Little","year":"2008","unstructured":"Little JL, Wheeler FB, Koumenis C, Kridel SJ (2008) Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell death. Mol Cancer Ther 7(12):3816\u20133824. https:\/\/doi.org\/10.1158\/1535-7163.mct-08-0558","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"3620_CR43","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1158\/1078-0432.ccr-03-0561","volume":"10","author":"XY Pei","year":"2004","unstructured":"Pei XY, Dai Y, Grant S (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10(11):3839\u20133852. https:\/\/doi.org\/10.1158\/1078-0432.ccr-03-0561","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3620_CR44","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s10637-013-0029-6","volume":"31","author":"WR Schelman","year":"2013","unstructured":"Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH (2013) A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Invest New Drugs 31(6):1539\u20131546. https:\/\/doi.org\/10.1007\/s10637-013-0029-6","journal-title":"Invest New Drugs"},{"key":"3620_CR45","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3389\/fimmu.2019.00588","volume":"10","author":"C Flores","year":"2019","unstructured":"Flores C, Fouquet G, Moura IC, Maciel TT, Hermine O (2019) Lessons to learn from low-dose cyclosporin-A: a new approach for unexpected clinical applications. Front Immunol 10:588. https:\/\/doi.org\/10.3389\/fimmu.2019.00588","journal-title":"Front Immunol"},{"key":"3620_CR46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40164-017-0073-6","volume":"6","author":"Y Isshiki","year":"2017","unstructured":"Isshiki Y, Tanaka H, Suzuki Y, Yoshida Y (2017) Cyclosporine is a potential curative treatment option for advanced thymoma. Exp Hematol Oncol 6:13. https:\/\/doi.org\/10.1186\/s40164-017-0073-6","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"3620_CR47","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0169-5002(97)00061-5","volume":"18","author":"HJ Ross","year":"1997","unstructured":"Ross HJ, Cho J, Osann K, Wong SF, Ramsinghani N, Williams J, Downey-Hurtado N, Slater LM (1997) Phase I\/II trial of low dose cyclosporin A with EP for advanced non-small cell lung cancer. Lung Cancer 18(2):189\u2013198","journal-title":"Lung Cancer"},{"key":"3620_CR48","doi-asserted-by":"publisher","DOI":"10.7717\/peerj-cs.67","author":"J Anaya","year":"2016","unstructured":"Anaya J (2016) OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Comput Sci. https:\/\/doi.org\/10.7717\/peerj-cs.67","journal-title":"PeerJ Comput Sci"},{"issue":"18","key":"3620_CR49","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","volume":"32","author":"GY Di Veroli","year":"2016","unstructured":"Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, Jodrell DI (2016) Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics 32(18):2866\u20132868. https:\/\/doi.org\/10.1093\/bioinformatics\/btw230","journal-title":"Bioinformatics"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-020-03620-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-020-03620-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-020-03620-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T23:52:21Z","timestamp":1629935541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-020-03620-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,26]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["3620"],"URL":"https:\/\/doi.org\/10.1007\/s00018-020-03620-w","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,26]]},"assertion":[{"value":"5 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Yosef Landesman is an employee of Karyopharm Therapeutics. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All in vivo experiments were performed in compliance with ethical regulations of Institutional Animal Care and Use Committee (IACUC) of National University of Singapore.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}